Melbourne researchers have shown they can stop leukaemia in its tracks by targeting a protein that puts the handbrake on cancer cell growth.
The researchers discovered that targeting a protein called Hhex could cure acute myeloid leukaemia (AML) in preclinical disease models, and could be a key target for new therapies for human leukaemia.
Dr Ben Shields and Dr Matt McCormack from the Walter and Eliza Hall Institute’s Cancer and Haematology division discovered that loss of the Hhex protein put the handbrake on leukaemia cell growth and division. The protein is a critical factor enabling AML cells to grow uncontrollably, a hallmark of cancer.
AML is an aggressive blood cancer that appears suddenly, grows quickly and has a poor prognosis. Existing treatments for AML are associated with serious side-effects. About three quarters of patients relapse after only a short period of treatment, with a five-year survival rate of just 24 per cent.
Dr McCormack said discovering how AML overcame normal cellular controls on growth and division was a breakthrough in the search for new therapies.
“There is an urgent need for new therapies to treat AML,” said Dr McCormack. “We showed blocking the Hhex protein could put the brakes on leukaemia growth and completely eliminate AML in preclinical models. This could be targeted by new drugs to treat AML in humans.”
He said Hhex was a particularly attractive therapeutic target because it was overproduced in leukaemia and, while essential for leukaemia cell growth, was not needed by healthy blood cells.
“Most existing treatments for AML are not cancer cell-specific, and unfortunately kill off healthy cells in the process,” Dr McCormack said.
“Hhex is only essential for the leukaemic cells, meaning we could target and treat leukaemia without toxic effects on normal cells, avoiding many of the serious side-effects that come with standard cancer treatments. We also know that most people with AML have increased levels of Hhex, often associated with adverse outcomes, further indicating it is an important target for new AML drugs.”
Dr Shields said AML cells switched off the controls that strictly manage cell growth and division. “Every cell has control genes that are activated when a cell is stressed, such as in the early stages of cancer, and stop the damaged cell from reproducing.” Dr Shields said.
While these control genes are still present in AML cells, they are switched off through a process called epigenetic modification. “Hhex works by recruiting epigenetic factors to growth control genes, effectively silencing them. This allows the leukaemia cells to reproduce and accumulate more damage, contributing to the speed of AML progression,” Dr Shields said.
Dr McCormack said drugs that inhibit epigenetic modification had been previously used to treat AML, but caused significant toxicity because their targets were also required for normal blood cell function.
“Unlike the epigenetic factors targeted previously, Hhex only regulates a small number of genes and is dispensable for normal blood cells. This gives us a rare opportunity to kill AML cells without causing many side effects,” said Dr McCormack. “We now hope to identify the critical regions of the Hhex protein that enable it to function, which will allow us to design much-needed new drugs to treat AML.”
The Latest on: Leukaemia
via Google News
The Latest on: Leukaemia
- Watch heart-melting moment leukaemia sufferer Abbie Bickley receives message from Santaon September 20, 2020 at 9:30 pm
This is the touching moment a brave 11-year-old girl battling leukaemia for a second time received a heart-warming message from Santa Claus. Abbie Bickley's face beamed as she watched the message ...
- Leukaemia battle: Sydney girl Ivy Hyde braver than a Disney princesson September 18, 2020 at 1:00 pm
Kathryn Huntley Leukaemia Foundation says as restrictions ease, blood cancer medical centres are bracing for a steep rise in the number of Australians requiring treatment ...
- Mom Gives 6-Year-Old Son Battling Leukaemia Custom Bear With Late Grandpa's Voiceon September 16, 2020 at 8:46 pm
An Ohio woman filmed the moment she gave her six-year-old leukaemia-battling son a custom-made bear to help him through the loss of his grandfather to COVID -19-induced complications. When Jessica ...
- Four-year-old boy who has beaten leukaemia twice starts first day of schoolon September 16, 2020 at 2:15 pm
A brave little boy who has beaten leukaemia twice in his short life has defied the odds - to start his first day of school today (weds). Mum Kirsty Knighton said there were times she had thought she ...
- Boy, 4, who defied the odds to twice beat leukaemia enjoys first day of schoolon September 16, 2020 at 12:39 pm
A BOY of four who defied the odds to twice beat leukaemia enjoyed his first day of school. Josh Stockhill’s parents admitted they had sometimes feared they would never see him in a uniform. Josh ...
- Cancer survivor’s child raises funds for leukaemia-hit teenon September 14, 2020 at 4:07 pm
Hyderabad: A 14-year-old student, whose mother conquered cancer, is now funding the treatment of a boy from Coimbatore.
- I went blind overnight at the age of 29 – it turned out to be leukaemia that had turned my blood to ‘porridge’on September 14, 2020 at 8:13 am
It was then that George was given the news that he was suffering from leukaemia. Doctors explained to George that the bleed had caused a high blood count that made his blood thick and “porridge ...
- I went blind overnight at the age of 29 – it turned out to be leukaemia that had turned my blood to ‘porridge’on September 14, 2020 at 4:09 am
A POLICE officer lost his eyesight overnight after leukaemia turned his blood to “porridge”. George Attwood had been working a night shift when his vision became blurry. The officer was unable to ...
- Restaurant owner says battling leukaemia 'felt like a lockdown'on September 12, 2020 at 3:00 pm
When SA went into lockdown in March, it was groundhog day for Cape Town restaurant owner Massimo Orione. In 2012, Orione spent several months in isolation in his native Italy after a bone marrow ...
- Leukaemia Therapeutics Market 2020: Trends, Share, Size and Forecast Report By 2022on September 11, 2020 at 12:18 am
Sep 11, 2020 (AmericaNewsHour) -- Leukaemia is the cancer of blood cells. Blood cells originate from HSCs, hematopoietic stem cells, in the bone marrow. Thereafter they undergo maturation process ...
via Bing News